Paxalisib Shows 100% Clinical Benefit in Advanced TNBC, 83% Objective Response
KZIA has more than doubled off its 52-week low of $4.86.
Summary
Kazia reported early Phase 1b data for paxalisib in Stage IV triple-negative breast cancer: all six evaluable patients achieved clinical benefit, with five objective responses (one complete, four partial) for an 83% ORR. No treatment-related serious adverse events were observed. Translational data showed median 83% reduction in CTC clusters and 51% reduction in terminally exhausted T cells, suggesting dual immune restoration and anti-metastatic effects. This is the first clinical efficacy readout for paxalisib in TNBC and materially de-risks the program. Enrollment completion is expected by July 2027, with interim updates throughout 2026-2027. The stock is trading near its 52-week high, reflecting high expectations; these results validate the thesis but the small sample size warrants caution.
At the time of this announcement, KZIA was trading at $16.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166.8M. The 52-week trading range was $4.86 to $17.40. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.